The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization
| Autor: | Ataullakhanov Ravshan I, Olga A. Smirnova, Natalia Petrakova, Maria G. Isaguliants, Alla A. Kushch, O. V. Masalova, Alexander V. Ivanov, E. I. Lesnova, Vadim V. Grabovetsky, Tatiana Mikhailovna Melnikova, A.V. Pichugin, Alexei D. Zaberezhny |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
CD4-Positive T-Lymphocytes
Viral Hepatitis Vaccines viruses Immunization Secondary Peptidoglycan CD8-Positive T-Lymphocytes Viral Nonstructural Proteins Biology Epitope Cell Line law.invention DNA vaccination Epitopes Interferon-gamma Mice chemistry.chemical_compound Th2 Cells Adjuvants Immunologic law Interferon Vaccines DNA medicine Animals Humans NS5A Antigens Viral Cell Proliferation General Veterinary General Immunology and Microbiology Immunogenicity Public Health Environmental and Occupational Health virus diseases biochemical phenomena metabolism and nutrition Hepatitis C Virology Molecular biology Recombinant Proteins digestive system diseases Infectious Diseases chemistry Mice Inbred DBA Naked DNA Recombinant DNA Interleukin-2 Molecular Medicine Female DNA medicine.drug |
| Zdroj: | Vaccine. 28:1987-1996 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2009.10.097 |
| Popis: | The aim of this study was to evaluate the immunogenicity of NS5A protein of human hepatitis C virus (HCV) when delivered as naked DNA (NS5A DNA), or recombinant protein (rNS5A). DBA/2J mice received NS5A DNA, rNS5A, or NS5A DNA/rNS5A in different prime-boost combinations with a peptidoglycan Immunomax((R)). The weakest response was induced after rNS5A prime and NS5A DNA boost; rNS5A alone induced an immune response with a strong Th2-component; and NS5A DNA alone, a relatively weak secretion of IL-2 and IFN-gamma. The most efficient was co-injection of NS5A DNA and rNS5A, which induced a significant increase in CD4(+) and CD8(+) T-cell counts, anti-NS5A antibodies, specific T-cell proliferation, and proinflammatory cytokine production in vitro against a broad spectrum of NS5A epitopes. Administration of the mixture of adjuvanted DNA and protein immunogens can be selected as the best regimen for further preclinical HCV-vaccine trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect